In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …
M Galluzzo, S D'Adamio, D Silvaggio… - Expert Opinion on …, 2020 - Taylor & Francis
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
TY Ger, YH Huang, RC Hui, TF Tsai… - … advances in chronic …, 2019 - journals.sagepub.com
Background: Little is known about the treatment outcomes of secukinumab in clinical
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …
Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real‐world practice
J Zhou, Y Yuan, Y Liu, M Chu, H Liu… - Experimental …, 2024 - Wiley Online Library
A number of randomized controlled trials and real‐world studies have demonstrated the
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …
Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that …
N Rompoti, P Sidiropoulou, P Panagakis… - Journal of the …, 2020 - Wiley Online Library
Background Few studies have investigated the long‐term outcomes of secukinumab in real‐
life psoriasis treatment where diverse patient profiles require a personalized approach …
life psoriasis treatment where diverse patient profiles require a personalized approach …
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
M Megna, L Di Costanzo, G Argenziano… - Expert Opinion on …, 2019 - Taylor & Francis
Background: Long term data on the real-life use of secukinumab are scant. The aim of this
study was to investigate the real-life effectiveness, safety and treatment persistence of …
study was to investigate the real-life effectiveness, safety and treatment persistence of …
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
L Cai, JZ Zhang, X Yao, J Gu, QZ Liu… - Chinese Medical …, 2020 - mednexus.org
Background: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the
Chinese population. Many patients are not well controlled by conventional treatments, thus …
Chinese population. Many patients are not well controlled by conventional treatments, thus …
[HTML][HTML] Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials
HZ Xiong, JY Gu, ZG He, WJ Chen… - … journal of clinical and …, 2015 - ncbi.nlm.nih.gov
Psoriasis is a chronic inflammatory skin disease with high rate of recurrence. New anti-
interleukin-17 (IL-17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove …
interleukin-17 (IL-17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove …
Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East regions: results from the REALIA study
P Foley, TF Tsai, K Rodins, IR Hamadah… - Dermatology and …, 2022 - Springer
Introduction Secukinumab has demonstrated sustained long-term efficacy with a favourable
safety profile in various manifestations of psoriatic disease. We investigated effectiveness …
safety profile in various manifestations of psoriatic disease. We investigated effectiveness …
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: a retrospective multicenter study
JF Schwensen, A Clemmensen, C Sand… - Dermatologic …, 2017 - Wiley Online Library
Abstract Secukinumab (anti‐IL17A) is effective as treatment for moderate to severe plaque
psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life …
psoriasis, but real‐life data on effectiveness and safety lack. We aimed to present real‐life …
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
J Notario, G Deza, E Vilarrasa, F Valentí… - Journal of …, 2019 - Taylor & Francis
Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO)
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …
相关搜索
- plaque psoriasis safety of secukinumab
- plaque psoriasis chinese patients
- analysis of subgroups secukinumab for psoriasis
- plaque psoriasis high efficacy
- real life safety of secukinumab
- meta analysis secukinumab in the treatment
- clinical setting secukinumab for psoriasis
- italian patients safety of secukinumab
- plaque psoriasis meta analysis
- plaque psoriasis optimal response
- meta analysis efficacy and safety
- plaque psoriasis drug survival
- chinese patients high efficacy
- real life southern italy
- effectiveness and safety secukinumab for psoriasis
- plaque psoriasis effectiveness and safety